Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Sadoff J, Le Gars M, Brandenburg B, Cárdenas V, Shukarev G, Vaissiere N, Heerwegh D, Truyers C, de Groot AM, Jongeneelen M, Kaszas K, Tolboom J, Scheper G, Hendriks J, Ruiz-Guiñazú J, Struyf F, Van Hoof J, Douoguih M, Schuitemaker H. Sadoff J, et al. Among authors: schuitemaker h. Vaccine. 2022 Jul 30;40(32):4403-4411. doi: 10.1016/j.vaccine.2022.05.047. Epub 2022 Jun 3. Vaccine. 2022. PMID: 35667914 Free PMC article.
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H. Widjojoatmodjo MN, et al. Among authors: schuitemaker h. Vaccine. 2015 Oct 5;33(41):5406-5414. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28. Vaccine. 2015. PMID: 26319741 Free article.
Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D. Sanders BP, et al. Among authors: schuitemaker h. Vaccine. 2015 Nov 27;33(48):6611-6. doi: 10.1016/j.vaccine.2015.10.091. Epub 2015 Nov 1. Vaccine. 2015. PMID: 26529068
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhoven W, Truyers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguih M, Ewer K, Angus B, Pollard AJ, Snape MD. Milligan ID, et al. Among authors: schuitemaker h. JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218. JAMA. 2016. PMID: 27092831 Clinical Trial.
Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
Khan S, Oosterhuis K, Wunderlich K, Bunnik EM, Bhaggoe M, Boedhoe S, Karia S, Steenbergen RDM, Bosch L, Serroyen J, Janssen S, Schuitemaker H, Vellinga J, Scheper G, Zahn R, Custers J. Khan S, et al. Among authors: schuitemaker h. Int J Cancer. 2017 Jul 15;141(2):393-404. doi: 10.1002/ijc.30679. Epub 2017 Apr 24. Int J Cancer. 2017. PMID: 28263390
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group. Baden LR, et al. Among authors: schuitemaker h. J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212. J Infect Dis. 2018. PMID: 29669026 Free PMC article. Clinical Trial.
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.
Vujadinovic M, Khan S, Oosterhuis K, Uil TG, Wunderlich K, Damman S, Boedhoe S, Verwilligen A, Knibbe J, Serroyen J, Schuitemaker H, Zahn R, Scheper G, Custers J, Vellinga J. Vujadinovic M, et al. Among authors: schuitemaker h. Vaccine. 2018 Jul 16;36(30):4462-4470. doi: 10.1016/j.vaccine.2018.06.024. Epub 2018 Jun 18. Vaccine. 2018. PMID: 29914845 Free article.
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge.
van der Lubbe JEM, Huizingh J, Verspuij JWA, Tettero L, Schmit-Tillemans SPR, Mooij P, Mortier D, Koopman G, Bogers WMJM, Dekking L, Meijberg W, Kwaks T, Brandenburg B, Tolboom JTBM, Schuitemaker H, Roozendaal R, Kuipers H, Zahn RC. van der Lubbe JEM, et al. Among authors: schuitemaker h. NPJ Vaccines. 2018 Jul 3;3:25. doi: 10.1038/s41541-018-0063-7. eCollection 2018. NPJ Vaccines. 2018. PMID: 29977611 Free PMC article.
363 results